Johns Hopkins researchers reported a biodegradable, polymer‑based nanoparticle that delivers mRNA encoding an anti‑CD19 chimeric antigen receptor (CAR) directly into T cells in vivo, producing functional CAR‑T cells that depleted B cells in mice. The work, published in Science Advances, presents an alternative to costly ex‑vivo CAR‑T manufacturing. The nanoparticles target and transiently reprogram circulating T cells to express the therapeutic CAR, which then seeks and destroys CD19‑expressing B cells—an approach relevant to autoimmune diseases and B‑cell malignancies. The team emphasized scalability and potential to reduce logistical barriers tied to current CAR‑T production. Translational steps remain: safety, dosing, and long‑term persistence must be addressed in larger animal studies before human testing. If the approach advances clinically, it could reshape access and cost models for cell therapies.